Bristol Myers Squibb's Revlimid revenues 2008-2023

Published by
Matej Mikulic,
Feb 15, 2024
This statistic reveals the revenues generated by top product Revlimid from 2008 to 2023. In 2023, one of the leading cancer drugs globally generated revenues of about six billion U.S. dollars. Revenues dropped dramatically since the launch of a generic version of the drug in March 2022. Revlimid was developed by Celgene Corporation, a former company headquartered in Summit, New Jersey. The company was specialized on drug manufacturing for cancer and inflammatory disorders. During 2019, the company was acquired by Bristol Myers Squibb.

Revenue of top product Revlimid from 2008 to 2023 (in million U.S. dollars)

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

February 2024

Region

Worldwide

Survey time period

2008 to 2023

Supplementary notes

The statistic was assembled from several annual reports.
* Transition year (BMS' acquisition of Celgene); value is rounded.
** Year of first generic version on the market.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Top pharmaceutical drugs "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Top pharmaceutical drugs

Global overview

3

Top companies' top products

5

Best-selling drugs

7

U.S. overview

5

Outlook

5

Further related statistics

19

Further Content: You might find this interesting as well

Statistics

Topics

Bristol-Myers SquibbGlobal pharmaceutical industryPharmaceutical industry in the U.S.Johnson & JohnsonRoche
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.
Menu